465 related articles for article (PubMed ID: 24898058)
61. A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies.
Ramesh S; Almeida SD; Hammigi S; Radhakrishna GK; Sireesha G; Panneerselvam T; Vellingiri S; Kunjiappan S; Ammunje DN; Pavadai P
Drug Res (Stuttg); 2023 Nov; 73(9):491-505. PubMed ID: 37890514
[TBL] [Abstract][Full Text] [Related]
62. Quantitation of Poly(ADP-Ribose) by Isotope Dilution Mass Spectrometry.
Zubel T; Martello R; Bürkle A; Mangerich A
Methods Mol Biol; 2017; 1608():3-18. PubMed ID: 28695499
[TBL] [Abstract][Full Text] [Related]
63. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
64. Poly(ADP-ribose): Structure, Physicochemical Properties and Quantification In Vivo, with Special Reference to Poly(ADP-ribose) Binding Protein Modules.
Miwa M; Ida C; Yamashita S; Tanaka M; Fujisawa J
Curr Protein Pept Sci; 2016; 17(7):683-692. PubMed ID: 27817744
[TBL] [Abstract][Full Text] [Related]
65. Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Heer CD; Sanderson DJ; Voth LS; Alhammad YMO; Schmidt MS; Trammell SAJ; Perlman S; Cohen MS; Fehr AR; Brenner C
J Biol Chem; 2020 Dec; 295(52):17986-17996. PubMed ID: 33051211
[TBL] [Abstract][Full Text] [Related]
66. Methods for purification of proteins associated with cellular poly(ADP-ribose) and PARP-specific poly(ADP-ribose).
Rood JE; Leung AK; Chang P
Methods Mol Biol; 2011; 780():153-64. PubMed ID: 21870260
[TBL] [Abstract][Full Text] [Related]
67. Poly ADP-ribosylation reaction.
Shall S
Jpn J Cancer Res; 1992 Apr; 83(4):inside front cover. PubMed ID: 1506263
[No Abstract] [Full Text] [Related]
68. Poly(ADP-ribose) signaling in cell death.
Virág L; Robaszkiewicz A; Rodriguez-Vargas JM; Oliver FJ
Mol Aspects Med; 2013 Dec; 34(6):1153-67. PubMed ID: 23416893
[TBL] [Abstract][Full Text] [Related]
69. New Insights into the Roles of NAD+-Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase.
Tanuma S; Sato A; Oyama T; Yoshimori A; Abe H; Uchiumi F
Curr Protein Pept Sci; 2016; 17(7):668-682. PubMed ID: 27817743
[TBL] [Abstract][Full Text] [Related]
70. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
71. Poly(ADP-ribose) polymerases covalently modify strand break termini in DNA fragments in vitro.
Talhaoui I; Lebedeva NA; Zarkovic G; Saint-Pierre C; Kutuzov MM; Sukhanova MV; Matkarimov BT; Gasparutto D; Saparbaev MK; Lavrik OI; Ishchenko AA
Nucleic Acids Res; 2016 Nov; 44(19):9279-9295. PubMed ID: 27471034
[TBL] [Abstract][Full Text] [Related]
72. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
73. Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.
Horvath EM; Zsengellér ZK; Szabo C
Methods Mol Biol; 2017; 1608():19-26. PubMed ID: 28695500
[TBL] [Abstract][Full Text] [Related]
74. ADP-Ribosylated Peptide Enrichment and Site Identification: The Phosphodiesterase-Based Method.
Daniels CM; Ong SE; Leung AKL
Methods Mol Biol; 2017; 1608():79-93. PubMed ID: 28695505
[TBL] [Abstract][Full Text] [Related]
75. Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases.
Hassler M; Ladurner AG
Curr Opin Struct Biol; 2012 Dec; 22(6):721-9. PubMed ID: 22985748
[TBL] [Abstract][Full Text] [Related]
76. Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation.
Barkauskaite E; Jankevicius G; Ahel I
Mol Cell; 2015 Jun; 58(6):935-46. PubMed ID: 26091342
[TBL] [Abstract][Full Text] [Related]
77. Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation.
Lu AZ; Abo R; Ren Y; Gui B; Mo JR; Blackwell D; Wigle T; Keilhack H; Niepel M
Biochem Pharmacol; 2019 Sep; 167():97-106. PubMed ID: 31075269
[TBL] [Abstract][Full Text] [Related]
78. Apurinic/apyrimidinic (AP) site recognition by the 5'-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1).
Khodyreva SN; Prasad R; Ilina ES; Sukhanova MV; Kutuzov MM; Liu Y; Hou EW; Wilson SH; Lavrik OI
Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22090-5. PubMed ID: 21127267
[TBL] [Abstract][Full Text] [Related]
79. Immunochemical analysis of poly(ADP-ribosyl)ation in HaCaT keratinocytes induced by the mono-alkylating agent 2-chloroethyl ethyl sulfide (CEES): Impact of experimental conditions.
Debiak M; Lex K; Ponath V; Burckhardt-Boer W; Thiermann H; Steinritz D; Schmidt A; Mangerich A; Bürkle A
Toxicol Lett; 2016 Feb; 244():72-80. PubMed ID: 26383632
[TBL] [Abstract][Full Text] [Related]
80. Insights into the biogenesis, function, and regulation of ADP-ribosylation.
Cohen MS; Chang P
Nat Chem Biol; 2018 Feb; 14(3):236-243. PubMed ID: 29443986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
